Every month, Lectra — the French software-and-cutting-equipment company for the fashion, automotive and furniture industries — files a one-page note stating exactly how many shares and voting rights it has. The August 31, 2026 version is what the most recent one looks like: a total of 38.06 million shares, gross voting rights equal to the share count, and net voting rights a fraction of a percent lower because the company holds a tiny block of its own shares in treasury.
A shareholder in that position naturally looks for the number that matters to them: is the count rising (dilution) or falling (buyback)? The honest answer is neither, at a scale that matters. The gap between gross and net voting rights — about 42,000 shares, or 0.1% of the capital — tells you how little of Lectra is sitting in its own treasury on any given month. The company runs a buyback program, authorized at its April 2026 shareholder meeting and disclosed in weekly blocks, but in the first half of 2026 it spent just €13.6 million on repurchases. That is real money but small against a market capitalization near €0.8 billion; it is not the event that moves per-share value.
Which is exactly why the monthly declaration is worth stopping on. The share count does not move because the buyback is tiny, and the buyback is tiny because Lectra is not using its cash to shrink its share base. It is using the cash somewhere else.
Consider what the company actually did with its money in the first half of 2026. It generated €24.5 million of free cash flow before non-recurring items. In the same six months it paid the fiscal-2025 dividend of €13.3 million, made two acquisition instalments — €19.5 million for the rest of TextileGenesis and €22.6 million for Launchmetrics — and repaid €8 million of debt. In other words, the cash out the door on those lines alone came to well over €70 million against €24.5 million generated, the difference funded out of the balance sheet. Lectra has long carried net cash, and it still reported €64.3 million of net cash at June 30, 2026. That cushion is the floor; it is also what makes the capital spending possible.
So the real question the filing raises is not how many shares there are, but what the reinvestment is buying. Here is the tension in the H1 numbers. Total revenue was €239.6 million, down 6% on a like-for-like basis, because the cyclical equipment side — the CAD/CAM cutting machines and consumables — shrank 26% like-for-like. The software side held up: recurring revenue of €190 million, 79% of the total, grew 2% like-for-like, and the SaaS slice within it grew 14%, leaving annual recurring revenue (ARR) at €102.6 million. Net income still fell to €9.7 million from €11.1 million a year earlier, because the equipment decline outweighed the software growth for now.
That is the mechanism the 2026–2028 roadmap is built on. Management's stated ambition is to compound SaaS ARR around 15% a year, grow recurring contract revenue 5–8% a year, and lift the EBITDA margin by 120–180 basis points a year, on the assumption the equipment business merely stabilizes rather than recovers. If software growth keeps rolling while the equipment drag fades — or, better, if equipment orders rebound — the per-share earnings that the market is paying for arrive. If instead the equipment decline keeps biting and SaaS growth decelerates from the mid-teens it has been running, the H1 pattern of falling net income extends and the multiple supporting the price has nothing to grow into.
Which brings up the price. At around €21.50 with a market cap near €0.8 billion, Lectra trades at roughly 13 times the trailing twelve-month EBITDA and somewhere in the low-to-mid 30s on trailing earnings, with a trailing P/E in the 20s on forecast earnings. The dividend of €0.35 a share yields only about 1.6%. Nothing about that is cheap, and nothing about it makes Lectra an income holding — the payout is a small, covered token, not the point of owning the stock.
The point is that you are buying a quality franchise mid-transition at a price already granting it the software future it hopes to reach. The value case rests on a test, not on the low multiple that would tempt a value buyer here: can the recurring revenue base compound as management plans, fast enough and long enough to outrun the equipment cycle and restore earnings growth? The net cash on the balance sheet and the recurring revenue mix argue the company can survive the transition; they do not by themselves say the price is right. If you believe the 2026–2028 growth assumptions, the shares are a reasonable bet on a durable compounder. If you think the equipment cycle stays soft and SaaS growth cools, the monthly declaration will still show 38 million shares — but the cash funneled into acquisitions and a shrinking profit would make you wonder what the waiting bought.
